June 2022

Study Reveals Metformin Does Not Diminish Risk for MACE
Clinical evidence reveals that both lifestyle intervention and metformin are beneficial in the prevention of diabetes; however, their efficacy in thwarting cardiovascular disease associated with the development of diabetes is unclear. In a recent publication, researchers investigated whether lifestyle intervention and use of metformin decreased the incidence of major cardiovascular events (MACE) over a 21-year median follow-up of trial participants. Read more.


FDA Approves Inhaled Treprostinil for PAH and PH-ILD
In a press release issued on May 24, 2022, the manufacturer, United Therapeutic Corporation, announced the FDA approval of Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Learn more about Tyvaso.

Elevated HDL-C and Outcomes in Patients With CAD
Previous studies have demonstrated lower cardiovascular risk with higher high-density lipoprotein cholesterol (HDL-C) levels; however, recent data in the general population have revealed a heightened risk of adverse outcomes with very high HDL-C concentrations. Learn more about what the authors concluded from findings in a recent cohort study of very high HDL-C levels and how paradoxically it is correlated with greater mortality risk in individuals with coronary artery disease (CAD).

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App